Caffeine Intake Alters Recovery Sleep after Sleep Deprivation.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
11 Oct 2024
Historique:
received: 23 09 2024
revised: 07 10 2024
accepted: 09 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

Caffeine is a well-known psychostimulant reputed to alleviate the deleterious effects of sleep deprivation. Nevertheless, caffeine can alter sleep duration and quality, particularly during recovery sleep. We evaluated the effects of acute caffeine intake on the duration and quality of recovery sleep following total sleep deprivation (TSD), taking into account daily caffeine consumption. Forty-one participants performed a double-blind, crossover TSD protocol (38 h of continuous wakefulness) with acute caffeine or placebo. Caffeine (2.5 mg/kg) or placebo was administered twice during continuous wakefulness (last treatment 6.5 h before bedtime for the recovery night). Polysomnographic measurements were recorded using a connected headband. TSD was associated with a rebound in total sleep time (TST) on the recovery night (+110.2 ± 23.2 min, Acute caffeine intake during TSD affects nighttime recovery sleep, with an interaction with daily consumption. These results may influence advice on caffeine intake for night-shift workers. (NCT03859882).

Sections du résumé

BACKGROUND BACKGROUND
Caffeine is a well-known psychostimulant reputed to alleviate the deleterious effects of sleep deprivation. Nevertheless, caffeine can alter sleep duration and quality, particularly during recovery sleep. We evaluated the effects of acute caffeine intake on the duration and quality of recovery sleep following total sleep deprivation (TSD), taking into account daily caffeine consumption.
METHODS METHODS
Forty-one participants performed a double-blind, crossover TSD protocol (38 h of continuous wakefulness) with acute caffeine or placebo. Caffeine (2.5 mg/kg) or placebo was administered twice during continuous wakefulness (last treatment 6.5 h before bedtime for the recovery night). Polysomnographic measurements were recorded using a connected headband.
RESULTS RESULTS
TSD was associated with a rebound in total sleep time (TST) on the recovery night (+110.2 ± 23.2 min,
CONCLUSIONS CONCLUSIONS
Acute caffeine intake during TSD affects nighttime recovery sleep, with an interaction with daily consumption. These results may influence advice on caffeine intake for night-shift workers. (NCT03859882).

Identifiants

pubmed: 39458438
pii: nu16203442
doi: 10.3390/nu16203442
pii:
doi:

Substances chimiques

Caffeine 3G6A5W338E
Central Nervous System Stimulants 0

Banques de données

ClinicalTrials.gov
['NCT03859882']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : General Directorate for Armament, Ministry of the Armies
ID : PDH-1-SMO-2-509).

Auteurs

Benoit Pauchon (B)

Ecole du Val de Grace, 75006 Paris, France.
Hôpital d'Instruction des Armées (HIA) Sainte Anne, 83100 Toulon, France.

Vincent Beauchamps (V)

Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Danielle Gomez-Mérino (D)

Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Mégane Erblang (M)

UMR LBEPS, Université Paris Saclay, 91000 Evry, France.

Catherine Drogou (C)

Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Pascal Van Beers (PV)

Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Mathias Guillard (M)

Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Michaël Quiquempoix (M)

Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Damien Léger (D)

URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.
APHP, Hôtel-Dieu, Centre du Sommeil et de la Vigilance, DMU THOROS, 75004 Paris, France.

Mounir Chennaoui (M)

Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Fabien Sauvet (F)

Ecole du Val de Grace, 75006 Paris, France.
Institut de Recherche Biomédicale des Armées (IRBA), 91190 Brétigny sur Orge, France.
URP 7330 VIFASOM, Université Paris Cité, Hôtel Dieu, 75004 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH